TABLE 1.
Baseline demographic of recipients/donors who underwent LDLT during COVID-19 pandemic
| Serial number | Age (y) | Sex | Cause | Reasons for transplant | MELD/PELD score/CTP | Date of transplant | IS regimen | Complications | Status | Donor age/sex | Relation to recipient |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Case 1 | 55 | F | HCV with HCC | Malignancy with recent AV embolization | 24/10 C | 24.3.2020 | CNI + MMF+steroid | None | Discharge | 31/M | Son |
| Case 2 | 15 | M | ALF | Acute liver failure | 31/14 C | 2.4.2020 | CNI + MMF+steroid | HAT | In patient | 41/F | Mother |
| Case 3 | 54 | F | HBV | Early chronic rejection | 16/9 B | 6.4.2020 | CNI + MMF+steroid | None | Discharge | 61/M | Husband |
| Case 4 | 49 | M | NASH | hyperbilirubinemia with recurrent HE | 28/12 C | 8.4.2020 | CNI + MMF+steroid | None | Discharge | 44/F | Wife |
| Case 5 | 65 | M | NASH | Multiple admissions for HE | 27/13 C | 10.4.2020 | CNI + MMF+steroid | None | Discharge | 35/M | Son |
| Case 6 | 56 | M | HBV + ethanol | Intractable pruritus | 26/10 C | 13.4.2020 | CNI + MMF+steroid | None | Discharge | 28/F | Daughter |
| Case 7 | 1.5 | M | Hepatoblastoma | Malignancy | 30/5 A | 22.4.2020 | CNI + MMF+Steroid | None | In patient | 30/F | Mother |
| Case 8 | 2 | M | Biliary atresia | Hyperbilirubinemia/recurrent cholangitis | 18/10 C | 24.4.2020 | CNI + MMF+steroid | None | In patient | 37/M | Uncle |
| Case 9 | 0.9 | F | Biliary atresia | Hyperbilirubinemia/UGI bleed | 19/11 C | 29.4.2020 | CNI + MMF+steroid | None | In patient | 30/F | Mother |
Abbreviations: ALF, acute liver failure; AV, arteriovenous; CNI, calcineurin inhibitors; COVID-19, coronavirus disease 2019; CTP, Child-Turcotte-Pugh; HAT, hepatic artery thrombosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HE, hepatic encephalopathy; IS, immunosuppressive regimen; LDLT, living donor liver transplant; MELD, Model for End-Stage Liver Disease; MMF, mycophenolate mofetil; NASH, nonalcoholic steatohepatitis; PELD, Pediatric End-Stage Liver Disease; UGI, upper gastrointestinal.